Ingelvac CircoFLEX
inactivated porcine circovirus vaccine
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Ingelvac CircoFLEX.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Ingelvac CircoFLEX.
For practical information about using Ingelvac CircoFLEX, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Ingelvac CircoFLEX
|
Agency product number |
EMEA/V/C/000126
|
Active substance |
porcine circovirus type 2 ORF2 protein
|
International non-proprietary name (INN) or common name |
inactivated porcine circovirus vaccine
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA07
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
13/02/2008
|
Contact address |
Product information
28/08/2019 Ingelvac CircoFLEX - EMEA/V/C/000126 - IA/0032/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
For active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2-related disease (PCVD).
In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.
Onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.